High-dose chemotherapy with stem cell rescue to treat stage III homologous deficient breast cancer: factors influencing clinical implementation

BACKGROUND: High-dose chemotherapy with autologous stem cell rescue (HDCT) is a promising treatment for patients with stage III, HER2-negative, homologous recombination deficient (HRD) breast cancer. Clinical effectiveness and cost-effectiveness are currently under investigation in an international...

Descripción completa

Detalles Bibliográficos
Autores principales: Verbeek, Joost G. E., de Jong, Vincent M. T., Wijnja, Hanna M., Jager, Agnes, Linn, Sabine C., Retèl, Valesca P., van Harten, Wim H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9824989/
https://www.ncbi.nlm.nih.gov/pubmed/36611165
http://dx.doi.org/10.1186/s12885-022-10412-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9824989/
https://www.ncbi.nlm.nih.gov/pubmed/36611165
http://dx.doi.org/10.1186/s12885-022-10412-x

Ejemplares similares